-

02:32:56 AM

AXLA Stock News

AXLA - Axcella Health Inc

01/23/23 4:15 PM

Nasdaq : AXLA

covid-19

Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

Axcella will be meeting with the MHRA in the near term to discuss the Innovative Licensing and Access Pathway application. The company further reported submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for a Phase 2 b/3 trial. Recent estimates indicate that 15-20% of Americans with COVID have persisting health...

RHEA-AI

neutral

12/14/22 8:01 PM

Nasdaq : AXLA

Axcella Announces Program Reprioritization and Corporate Restructuring

Axcella Therapeutics, a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announces a repositioning of its strategy to focus on Long COVID and realize value from its platform and current programs. “The strategic process we initiate today prioritizes...

RHEA-AI

positive

11/03/22 9:59 AM

Nasdaq : AXLA

conferences

Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases...

RHEA-AI

neutral

11/01/22 7:00 AM

Nasdaq : AXLA

earnings

Axcella Reports Third Quarter Financial Results and Provides Business Update

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. “This has been an extremely exciting period for Axcella,”...

RHEA-AI

neutral

10/27/22 8:30 AM

Nasdaq : AXLA

conferencesearnings

Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that it plans to report its third quarter 2022 financial results and other business updates on November 1, 2022. The company will host a conference call at...

RHEA-AI

neutral

10/14/22 1:24 PM

Nasdaq : AXLA

conferences

Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 6 th Annual NASH Investor Conference taking place...

RHEA-AI

neutral

10/13/22 8:00 AM

Nasdaq : AXLA

offeringmanagement

Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members

The Shares were offered pursuant to a shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission and declared effective by the SEC on June 12, 2020. A final prospectus supplement, which contains additional information relating to the offering, has been filed with the SEC and is available on the SEC’ s website at...

RHEA-AI

neutral

09/29/22 6:00 AM

Nasdaq : AXLA

clinical trial

Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today reported interim results from their ongoing global Phase 2 b randomized, double-blind, placebo-controlled, dose ranging EMMPACT study to evaluate the safety,...

RHEA-AI

positive

09/12/22 8:00 AM

Nasdaq : AXLA

conferences

Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place September...

RHEA-AI

neutral

08/12/22 7:30 AM

Nasdaq : AXLA

earnings

Axcella Reports Second Quarter Financial Results and Provides Business Update

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced financial results for the second quarter ended June 30, 2022 and provided a business update. Cash Position: As of June 30, 2022, cash, cash equivalents, and...

RHEA-AI

neutral

1 2 3 4 5 6 Next

AXLA Data

IndustryResearch and Development in Biotechnology
Websitewww.axcellahealth.com
Security nameAxcella Health Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2836
Employees59
Tags
- Pharmaceuticals: Major
- Biotechnology
- Health Technology

About Axcella Health Inc

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company's product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella's pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence.